Across Europe the demand for resources in the Health sector is growing faster than the supply, and there is a growing consensus that Digital Therapeutics Apps with their ability to reach a wide part of the population at scale, and in a cost efficient way, is part of the solution.
But development of medical grade apps, that have clinical evidence and satisfy the strictest quality standards is expensive, and vendors need to know how they can be adopted and reimbursed by the healthcare system, before they develop and deploy solutions that can benefit the patients.
SelfBack is an example of one of the few medical grade apps with clinical evidence. SelfBack takes part in the EU harmonisation work of Health Technology Assessments and in this session SelfBack will share their experience from different European countries, and give an overview of how the Swedish/Nordic market access, reimbursement and regulations compares to the rest of Europe from a manufactures point of view.